153 related articles for article (PubMed ID: 2702680)
1. The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients.
Cascinelli N; Rümke P; MacKie R; Morabito A; Bufalino R
Cancer Immunol Immunother; 1989; 28(4):282-6. PubMed ID: 2702680
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
[TBL] [Abstract][Full Text] [Related]
3. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
Wood WC; Cosimi AB; Carey RW; Kaufman SD
Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
[TBL] [Abstract][Full Text] [Related]
5. Value of adjuvant therapy with bacille Calmette Guerin (BCG) or dimethl triazeno imidazole carboximide (DTIC) in the control of minimal residual disease in stage II melanoma.
Peter HH; Deutschmann KE; Deinhardt J; Deicher H
Recent Results Cancer Res; 1978; 68():367-74. PubMed ID: 752872
[No Abstract] [Full Text] [Related]
6. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
[TBL] [Abstract][Full Text] [Related]
7. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
[TBL] [Abstract][Full Text] [Related]
9. [Current results with surgery and adjuvant chemotherapy in malignant melanoma].
Mechl Z; Kopecný J
Arch Geschwulstforsch; 1986; 56(5):367-71. PubMed ID: 2429631
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG.
Karakousis CP; Emrich LJ
J Surg Oncol; 1987 Dec; 36(4):235-8. PubMed ID: 3695527
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy.
Castel T; Estapé J; Viñolas N; Mascaró JM; Castro J; Vilalta A; Gratacós R; Daniels M; Palou J; Grau JJ
Dermatologica; 1991; 183(1):25-30. PubMed ID: 1769411
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
Abdi EA; Hanson J; McPherson TA
Am J Clin Oncol; 1987 Apr; 10(2):117-22. PubMed ID: 3565312
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
16. Chemoimmunotherapy for metastatic malignant melanoma using vincristine (NSC-67574), DTIC (NSC-45388) and Bacillus Calmette-Guerin.
Thatcher N; Blackledge G; Palmer MK; Crowther D
Eur J Cancer (1965); 1981 Apr; 17(4):465-9. PubMed ID: 7308256
[No Abstract] [Full Text] [Related]
17. Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guérin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma.
Tumori; 1984 Feb; 70(1):41-8. PubMed ID: 6369694
[TBL] [Abstract][Full Text] [Related]
18. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
Coates AS; Peters M
Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study.
Costanzi JJ; Al-Sarraf M; Groppe C; Bottomley R; Fabian C; Neidhart J; Dixon D
Med Pediatr Oncol; 1982; 10(3):251-8. PubMed ID: 7045615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
